For patients in the very early stages of mild cognitive impairment, prognosis can be gauged with PET imaging using two different tracers — fluorodeoxyglucose (FDG) and florbetapir, which measures beta-amyloid pathology — according to new research reported here at the Society of Nuclear Medicine and Molecular Imaging 2015 Annual Meeting. {read more here}

Researchers from the University of California, Los Angeles (UCLA) are adding to the evidence that amyloid PET imaging can be a valuable resource for diagnosing and treating Alzheimer’s disease. They presented their findings on Monday at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. {read more here}

Jeremy Howard Lewin, MD, of Peter MacCallum Cancer Center in East Melbourne, Australia, and colleagues conducted this retrospective study to assess disease sub-stage specific PET surveillance in a cohort of 86 patients with resected stage III melanoma. {read more here}

Sleep may be a missing piece in the Alzheimer’s disease puzzle.  UC Berkeley scientists have found compelling evidence that poor sleep — particularly a deficit of the deep, restorative slumber needed to hit the save button on memories — is a channel through which the beta-amyloid protein believed to trigger Alzheimer’s disease attacks the brain’s long-term memory.  {read more here}